• About Us
  • Our Editorial Policy
  • Business Directory
  • Advertise with Us
  • Our Advertisers
  • Contact Us
Australia India News
  • Alluring India - Brisbane Banner
India News Australia
  • Home
  • Current Issue
    Past Issue
  • India News
  • Business
  • World
    World This Week
  • Community News
  • What's On
  • Others
    Yoga in Australia News COVID-19 Community News Naari IPL News Health Travel Entertainment
  • National Events
  • Alluring India 2026
  • Please wait..
Business and Trade news

Maharashtra FDA bars sale of Cadila Pharmaceuticals drugs, seizes Rs 2.45 crore stock

  • BY India News Newsdesk
  • July 12, 2026
  • 0 COMMENTS

New Delhi, July 11 (IANS) The Maharashtra Food and Drug Administration (FDA) has barred the sale and distribution of certain medicines manufactured by Cadila Pharmaceuticals Ltd and seized stock worth around Rs 2.45 crore over concerns that similar branding could lead to medication errors, as per multiple reports.

It also directed the company to recall select products from the market, it added.

The action relates to Aciloc 150, Aciloc 150 Plus, Aciloc 300 and Aciloc 300 Plus, which contain different active pharmaceutical ingredients (APIs) despite having nearly identical branding.

According to the FDA, Aciloc 150 and Aciloc 300 were originally approved with Ranitidine as the active ingredient.

The company later introduced Aciloc 150 Plus and Aciloc 300 Plus containing Famotidine while retaining almost identical branding and artwork, except for the addition of the ‘+’ symbol.

The regulator said the simultaneous availability of the Ranitidine- and Famotidine-based medicines in the market could create confusion among doctors, pharmacists and patients, increasing the risk of dispensing or consuming the wrong medicine.

FDA Commissioner Tukaram Mundhe said any confusion caused by a medicine’s brand name that could result in doctors, pharmacists or patients receiving the wrong drug was a serious public health concern.

The FDA said it prohibited the sale and distribution of the available stock of the medicines during inspections carried out on July 9 and 10 at the company’s carrying and forwarding agent warehouses in Pune, Nagpur and Bhiwandi in Thane district.

The action covered medicine stock valued at Rs 2,45,37,490.

Existing guidelines prohibit marketing medicines with a changed composition under substantially the same brand name and added that the preventive action was initiated to safeguard public health, the regulator said.

The FDA said further investigation is underway and legal action will be taken under the Drugs and Cosmetics Act, 1940, and the rules framed thereunder based on the findings.

–IANS

ag/

Post navigation

CM Fadnavis dismisses speculation over shift to Centre with witty response
Archery World Cup: Teenager Prithika Pradeep claims bronze, powers India to compound team silver

Related Post

Govt’s eSaras platform boosts digital commerce for nearly 9 crore SHG members
July 12, 2026
HDFC Bank says legal review did not substantiate former chairman Atanu Chakraborty’s claims
July 12, 2026
Govt considers pilot AI data trust at IIT Hyderabad: Ashwini Vaishnaw
July 11, 2026
ONGC to develop 1.75 MMT strategic petroleum reserve at Mangaluru
July 11, 2026

Our Current Issue

Australia India News – July 1-15-2026

Alluring India 2026

Our Advertisers

  • Battery Rebate australia
  • Bess Australia Solar Panels
  • Alluring India - Brisbane 2026

Follow Us

  • facebook
  • facebook
  • facebook
  • facebook
INDIA NEWS on YouTube in Australia, bring to our readers and subscribers national and international news, editorials, expert columns, community activities and interviews of political leaders, celebrities, business professionals, academics and sport personalities among others.
  • facebook
  • facebook
  • facebook
  • facebook

Category

  • Accident
  • Adani Australia
  • Advertorial
  • Arts & Culture
  • Ashes 2022
  • Australia

Recent News

  • One-off Test: India 154/1 at stumps on...
  • ‘Does not want Muslim children to succeed’:...

Subscribe Newsletter

Get the latest creative news from india news

  • Privacy Policy
  • Disclaimer
Alluring India 2026